Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.

Thoueille, Paul; Saldanha, Susana Alves; Schaller, Fabian; Choong, Eva; Veuve, François; Munting, Aline; Cavassini, Matthias; Braun, Dominique; Günthard, Huldrych F; Duran Ramirez, Jessy J; Surial, Bernard; Furrer, Hansjakob; Rauch, Andri; Ustero, Pilar; Calmy, Alexandra; Stöckle, Marcel; Di Benedetto, Caroline; Bernasconi, Enos; Schmid, Patrick; Marzolini, Catia; ... (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. Clinical pharmacology and therapeutics, 115(6), pp. 1450-1459. Wiley 10.1002/cpt.3240

Preview

Text Clin_Pharma_and_Therapeutics_-_2024_-_Thoueille_-_Population_Pharmacokinetics_of_Cabotegravir_Following_Oral_Administration.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (1MB) | Preview

Long-acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real-world reference percentile curves of cabotegravir concentrations, accounting for patient-related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations. Overall, 238 PWH contributed to 1,038 cabotegravir levels (186 during the initial oral administration phase and 852 after intramuscular injection). Cabotegravir pharmacokinetics was best described using a one-compartment model with distinct first order-absorption for oral and intramuscular administrations, and identical volume and clearance. Our model showed almost 40% faster absorption and 30% higher clearance than previously reported, resulting in a time to steady-state of 8 months and an elimination half-life of 4.6 weeks for long-acting cabotegravir. Sex and body mass index significantly influenced absorption, and bodyweight affected clearance. Model-based simulations showed that cabotegravir trough concentrations in females were 25% lower 4 weeks after the intramuscular loading dose, but 42% higher during the late maintenance phase. Finally, simulations indicated that in females, despite significantly higher cabotegravir concentrations, longer intervals between injections may not consistently ensure levels above the 4-fold protein-adjusted 90% inhibitory target concentration.

Interest & Impact

Downloads

15 since deposited on 27 Mar 2024
15 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item